疾病在现实世界中找到了治疗的身份：在慢性咳嗽中使用吉法平昔。

IF 4 3区医学 Q1 RESPIRATORY SYSTEM

ERJ Open Research Pub Date : 2025-07-07 eCollection Date: 2025-07-01 DOI:10.1183/23120541.00096-2025

Yeonhee Kim, Woo-Jung Song

引用次数: 0

摘要

难治性或不明原因的慢性咳嗽作为一种独特的疾病实体正在获得认可。Gefapixant提供了有希望的靶向治疗，现实世界的证据突出了它在改善预后和促进我们对疾病理解方面的潜力。https://bit.ly/42U2p6j。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Disease finds its identity with treatment in the real world: the use of gefapixant in chronic cough.

查看原文本刊更多论文

Disease finds its identity with treatment in the real world: the use of gefapixant in chronic cough.

Refractory or unexplained chronic cough is gaining recognition as a distinct disease entity. Gefapixant offers promising targeted therapy, and real-world evidence highlights its potential in improving outcomes and advancing our disease understanding. https://bit.ly/42U2p6j.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ERJ Open Research Medicine-Pulmonary and Respiratory Medicine

CiteScore

6.20

自引率

4.30%

发文量

273

审稿时长

8 weeks

期刊介绍： ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.